个人中心 - 老虎社区

割肉刀

IP属地：广东

帖子 · 4帖子 · 4
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 割肉刀割肉刀
  ·2022-08-25
  $百奥赛图－Ｂ(02315)$$百奥赛图-B(02315)$ 蛮有意思的，有意思的是我倒不在乎他的抗体，adc，双抗平台，反而是用CRISPR技术建立这些平台，且用CRISPR敲基因去发现靶点，不知道CRISPR技术成熟了他会不会从抗体cxo直接蜕变成CRISPR公司有想法了解下。
  2,577 2
  点赞
  分享
  举报
- 割肉刀割肉刀
  ·2022-08-19
  $百奥赛图-B(02315)$正在招股中，于8月19日至8月24日招股，公司拟发行2175.85万股股份，其中公开发售217.6万股，国际发售1958.25万股，每股发行价25.22港元，每手500股，预期将于9月1日上市。招股书显示，在百奥赛图的收入结构中，以小鼠为主的模式动物的销售额在整体营收中占比达三成。其中，一只4-8周的B-NDG小鼠的平均单价在240-260元，4-8周人源化小鼠单价在1300-4700元。该业务毛利率高达76%。
  2,165 评论
  2
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3441930721947278","uuid":"3441930721947278","gmtCreate":1478836701523,"gmtModify":1660808568194,"name":"割肉刀","pinyin":"grdgeroudao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/1ffe3ab7aa36ce99eb1e4e2fc0ac5d07","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":4,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":660332592,"gmtCreate":1661417512621,"gmtModify":1661418466793,"author":{"id":"3441930721947278","authorId":"3441930721947278","name":"割肉刀","avatar":"https://static.tigerbbs.com/1ffe3ab7aa36ce99eb1e4e2fc0ac5d07","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3441930721947278","authorIdStr":"3441930721947278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02315\">$百奥赛图－Ｂ(02315)$</a>$百奥赛图-B(02315)$&nbsp;蛮有意思的，有意思的是我倒不在乎他的抗体，adc，双抗平台，反而是用CRISPR技术建立这些平台，且用CRISPR敲基因去发现靶点，不知道CRISPR技术成熟了他会不会从抗体cxo直接蜕变成CRISPR公司有想法了解下。","listText":"<a href=\"https://laohu8.com/S/02315\">$百奥赛图－Ｂ(02315)$</a>$百奥赛图-B(02315)$&nbsp;蛮有意思的，有意思的是我倒不在乎他的抗体，adc，双抗平台，反而是用CRISPR技术建立这些平台，且用CRISPR敲基因去发现靶点，不知道CRISPR技术成熟了他会不会从抗体cxo直接蜕变成CRISPR公司有想法了解下。","text":"$百奥赛图－Ｂ(02315)$$百奥赛图-B(02315)$ 蛮有意思的，有意思的是我倒不在乎他的抗体，adc，双抗平台，反而是用CRISPR技术建立这些平台，且用CRISPR敲基因去发现靶点，不知道CRISPR技术成熟了他会不会从抗体cxo直接蜕变成CRISPR公司有想法了解下。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/660332592","isVote":1,"tweetType":1,"viewCount":2577,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4123984768957422","authorId":"4123984768957422","name":"再买该剁手","avatar":"https://static.tigerbbs.com/b99c1091a9210eb84a7eb020769a3549","crmLevel":1,"crmLevelSwitch":0,"idStr":"4123984768957422","authorIdStr":"4123984768957422"},"content":"CRISPR只是基本技术工具，百奥赛图的目标是要成为药物开发公司，利用公司的模式动物优势，这个优势全球生物医药公司绝无仅有","text":"CRISPR只是基本技术工具，百奥赛图的目标是要成为药物开发公司，利用公司的模式动物优势，这个优势全球生物医药公司绝无仅有","html":"CRISPR只是基本技术工具，百奥赛图的目标是要成为药物开发公司，利用公司的模式动物优势，这个优势全球生物医药公司绝无仅有"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":687880702,"gmtCreate":1660873159110,"gmtModify":1660873359752,"author":{"id":"3441930721947278","authorId":"3441930721947278","name":"割肉刀","avatar":"https://static.tigerbbs.com/1ffe3ab7aa36ce99eb1e4e2fc0ac5d07","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3441930721947278","authorIdStr":"3441930721947278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02315\">$百奥赛图-B(02315)$</a>正在招股中，于8月19日至8月24日招股，公司拟发行2175.85万股股份，其中公开发售217.6万股，国际发售1958.25万股，每股发行价25.22港元，每手500股，预期将于9月1日上市。招股书显示，在百奥赛图的收入结构中，以小鼠为主的模式动物的销售额在整体营收中占比达三成。其中，一只4-8周的B-NDG小鼠的平均单价在240-260元，4-8周人源化小鼠单价在1300-4700元。该业务毛利率高达76%。","listText":"<a href=\"https://laohu8.com/S/02315\">$百奥赛图-B(02315)$</a>正在招股中，于8月19日至8月24日招股，公司拟发行2175.85万股股份，其中公开发售217.6万股，国际发售1958.25万股，每股发行价25.22港元，每手500股，预期将于9月1日上市。招股书显示，在百奥赛图的收入结构中，以小鼠为主的模式动物的销售额在整体营收中占比达三成。其中，一只4-8周的B-NDG小鼠的平均单价在240-260元，4-8周人源化小鼠单价在1300-4700元。该业务毛利率高达76%。","text":"$百奥赛图-B(02315)$正在招股中，于8月19日至8月24日招股，公司拟发行2175.85万股股份，其中公开发售217.6万股，国际发售1958.25万股，每股发行价25.22港元，每手500股，预期将于9月1日上市。招股书显示，在百奥赛图的收入结构中，以小鼠为主的模式动物的销售额在整体营收中占比达三成。其中，一只4-8周的B-NDG小鼠的平均单价在240-260元，4-8周人源化小鼠单价在1300-4700元。该业务毛利率高达76%。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/687880702","isVote":1,"tweetType":1,"viewCount":2165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}